Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis.

Area of Science:

• Pharmacovigilance
• Dermatology
• Oncology

Background:

• Rituximab is a monoclonal antibody used for malignancies and autoimmune diseases.
• Pyoderma gangrenosum is a rare, painful, and potentially fatal ulcerative condition that can recur.
• Identifying potential adverse drug reactions is crucial for patient safety.

Purpose of the Study:

• To investigate a potential association between Rituximab and pyoderma gangrenosum.
• To determine if a statistically significant signal exists in adverse event reporting data.

Main Methods:

• Disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
• Utilized frequentist (ROR, PRR) and Bayesian (IC025) methods for signal detection.
• Reviewed literature for supporting case reports.

Main Results:

• A statistically significant signal for pyoderma gangrenosum associated with Rituximab was identified in FAERS.
• Thirty-two cases reported the adverse event post-Rituximab administration.
• Six literature case reports detailed 14 patients with pyoderma gangrenosum after Rituximab.

Conclusions:

• The analysis indicates a statistically significant association between Rituximab and pyoderma gangrenosum.
• Clinicians should exercise caution and monitor for pyoderma gangrenosum symptoms in patients receiving Rituximab.
• Further investigation may be warranted to understand this adverse event.